Amicus Therapeutics is building momentum with strong sales growth from GALAFOLD and POMBILITI/OPFOLDA. Click here to find out ...

As you might know, Amicus Therapeutics, Inc. ( NASDAQ:FOLD ) just kicked off its latest second-quarter results ...

Learn more about whether ADMA Biologics, Inc. or Amicus Therapeutics, Inc. is a better investment based on AAII's A+ Investor ...

Amicus Therapeutics Inc (FOLD) reports its 17th consecutive quarter of double-digit revenue growth, while navigating increased operating expenses and ongoing litigation challenges.

Second Quarter 2025 Financial Highlights: Total revenues for the second quarter 2025 were $154.7 million, reflecting strong ...

Highlights,XTX Topco Ltd significantly increased its position in Amicus Therapeutics during the first quarter,Shares of ...

PRINCETON, N.J. (AP) — PRINCETON, N.J. (AP) — Amicus Therapeutics Inc. (FOLD) on Thursday reported a loss of $24.4 million in its second quarter. On a per-share basis, the Princeton, New Jersey-based ...

Amicus Therapeutics (FOLD) could be a solid choice for investors given the company's remarkably improving earnings outlook.

Amicus Therapeutics, Inc. (NASDAQ: FOLD) is one of the best strong buy stocks to buy under $10. In a report released on July ...

Amicus Therapeutics (($FOLD)) has held its Q2 earnings call. Read on for the main highlights of the call. Amicus Therapeutics’ recent earnings ...

Assetmark Inc. Scales Down Stake in Amicus Therapeutics Amid Strategic Portfolio Rebalancing | S&P 500 Futures Tracker ...

Investing.com - Morgan Stanley has upgraded Amicus Therapeutics (NASDAQ:FOLD) from Equalweight to Overweight with a price target of $12.00, citing the company’s strong intellectual property ...